Life Science Intelligence

Industry leaders from Intuitive Ventures, Hologic, Kx Advisors, and Illumicell AI discuss innovative funding strategies and technologies aimed at finally addressing the critical unmet needs in women’s health, moderated by RQM+’s Allison Komiyama. For more information watch this video here: https://www.lifesciencemarketresearch.com/videos/new-approaches-for-finally-funding-and-solving-unmet-needs-in-womens-health-lsi-usa-25

Industry leaders from Anthro Ventures, Rex Health Ventures, Catalyst Health Ventures, and Knobbe Martens discuss strategies for driving innovation, strategic investing, and impactful healthcare solutions heading into 2025. For more information watch this video here:  https://www.lifesciencemarketresearch.com/videos/navigating-innovation-investment-and-impact-in-2025-lsi-usa-25

In Q3 of 2025, LSI Alumni raised over $925 million across 40+ deals, including two M&A transactions and two IPOs. Our quarterly Alumni Funding Report features transactions made by these medical device startups and their investors. To view the full report with the deals, companies, and investors involved, sign up for a free Compass account here . Lucida Medical Lucida Medical was awarded a £2.25 million SBRI Healthcare contract to expand deployment of its AI-powered prostate cancer diagnostic platform across the NHS. The funding supports implementation of Lucida Medical’s Prostate Intelligence™ system in up to 15 hospitals, where it will accelerate diagnosis, reduce unnecessary biopsies, and improve access to earlier, more accurate care. Investors/Deal Details : Small Business Research Initiative (SBRI) Healthcare RECORNEA RECORNEA closed an oversubscribed €1.2 million Seed round to advance minimally invasive corneal disease therapies. The funding supports RECORNEA’s first-in-human ...

Under the direction of President and CEO Clément Vidal, eCential Robotics is creating a new standard in robot-assisted bone surgery. The Grenoble-based company has developed a universal, implant-agnostic platform that integrates real-time navigation and surgical robotics into a single interface, designed to make spine and orthopedic procedures safer, more efficient, and more consistent.  Origin Story eCential Robotics was founded in 2009 by Stéphane Lavallée, a pioneer in medical imaging, surgical robotics, and computer-assisted medical interventions. The company began with the goal of merging intraoperative imaging and navigation for bone surgery. Over time, robotics became an essential piece of the platform. “Now we are offering intraoperative imaging capabilities, surgical navigation, and robotics,” Vidal explained.  Vidal joined the company five years ago, drawn by its mission and technology. “What excited me was the idea of building enabling technology around an open plat...

 Under the direction of CEO David Carey, Preceptis Medical is transforming pediatric ear tube procedures with its HummingbirdⓇ Tympanostomy Tube System (TTS): a quick, general anesthesia-free, office-based solution that simplifies care for families and ENT surgeons. By eliminating the need for general anesthesia and the operating room, Hummingbird offers a more accessible and efficient approach to one of the most common pediatric procedures. As Carey puts it, “This is one of those unique products where everyone benefits.” Origin Story Preceptis Medical was founded by a pediatric anesthesiologist who saw firsthand the inefficiencies of a decades-old surgical standard. “He had just seen all of these cases where children were under general anesthesia, where there was 20 minutes of operating room setup for a five-minute procedure,” Carey explains. “He saw an opportunity to make things more efficient and more family-friendly.” That vision led to the development of Humming...

One of the most notable portfolio realignments in medtech this year comes from Johnson & Johnson MedTech, as the company prepares to separate its legacy orthopedics unit into a standalone business. The move caps nearly two years of internal restructuring and aligns with a wider industry pattern: leading strategics such as Stryker and Medtronic have been rebalancing their portfolios, spinning off slower-growth or non-core segments to focus resources on high-growth therapeutic markets. At first glance, divesting an operation as large and historic as Johnson & Johnson’s orthopedics business might appear counterintuitive. But a closer look at the numbers and competitive context reveals why the company views this as a strategic reset rather than a retreat. A Market Leader Ready for Independence J&J’s orthopedics division generated ~$9.2 billion in revenue in 2024, representing the single largest share of the ~$54 billion global orthopedics market, according to LSI Market Intelli...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $264M in new funding, announce regulatory clearances, enter new partnerships, and much more on the road to LSI USA ’26 in Dana Point (March 16–20). Augmedics Received FDA 510(k) clearance for X2™, its next-generation augmented reality (AR) surgical headset for use with the xvision Spine SystemⓇ. Purpose-built for the operating room, X2 enhances visualization, ergonomics, and performance for spine procedures. Cern Partnered with HITLAB to advance its light-based, non-drug treatment for recurrent vaginal infections using the Cern Device™, a novel at-home therapy. The collaboration will support validation efforts ahead of FDA review, focusing on usability, safety, and digital health integration. Clairity Raised $43M in Series B funding to commercialize Clairity Breast, the first FDA-authorized AI platform that predicts five-year breast cancer risk from a sta...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni announce regulatory wins, achieve clinical milestones, appoint new executives, and much more on the road to LSI USA ’26 in Dana Point (March 16–20). Avvio Medical Received FDA Breakthrough Device Designation for its Enhanced Lithotripsy System (ELS), a minimally invasive platform designed to treat kidney stones without general anesthesia, fluoroscopy, or costly capital equipment. The designation accelerates the company’s path to De Novo submission in 2026 and supports its mission to move kidney stone treatments out of the OR and into more accessible outpatient settings. Earlybird Health Promoted Dr. Rabab Nasrallah and LSI Alumni Dr. Christoph Massner to Partners at Earlybird Health in recognition of their leadership across biotech, medtech, and data-driven health investments. The promotion reflects their impact on investment strategy and portfolio management, further...